about
Expression of the leukemic prognostic marker CD7 is linked to epigenetic modifications in chronic myeloid leukemiaMicroRNAs enriched in hematopoietic stem cells differentially regulate long-term hematopoietic outputMUC1-C Oncoprotein Blocks Terminal Differentiation of Chronic Myelogenous Leukemia Cells by a ROS-Mediated MechanismMolecular mechanisms for survival regulation of chronic myeloid leukemia stem cellsRegulation of TGF-β Signal TransductionQuantitative phenotyping-based in vivo chemical screening in a zebrafish model of leukemia stem cell xenotransplantationOne more stem cell niche: how the sensitivity of chronic myeloid leukemia cells to imatinib mesylate is modulated within a "hypoxic" environment.Tumour heterogeneity and cancer cell plasticityA novel AHI-1-BCR-ABL-DNM2 complex regulates leukemic properties of primitive CML cells through enhanced cellular endocytosis and ROS-mediated autophagy.SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations.PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in miceSelenium suppresses leukemia through the action of endogenous eicosanoids.Age disparity in the dissemination of imatinib for treating chronic myeloid leukemiaProperties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylateUnusual case of simultaneous presentation of plasma cell myeloma, chronic myelogenous leukemia, and a jak2 positive myeloproliferative disorder.Characterization of chronic myeloid leukemia stem cells.Successful pregnancy in a patient with chronic myeloid leukaemia exposed to dasatinib during the first trimester.Terminal differentiation of chronic myelogenous leukemia cells is induced by targeting of the MUC1-C oncoprotein.Targeting the MYC and PI3K pathways eliminates leukemia-initiating cells in T-cell acute lymphoblastic leukemiaIL1RAP as a surface marker for leukemia stem cells is related to clinical phase of chronic myeloid leukemia patients.Oncogenic tyrosine kinases target Dok-1 for ubiquitin-mediated proteasomal degradation to promote cell transformationSynthesis and characterization of a BODIPY conjugate of the BCR-ABL kinase inhibitor Tasigna (nilotinib): evidence for transport of Tasigna and its fluorescent derivative by ABC drug transporters.Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cellsCelastrol and an EGCG pro-drug exhibit potent chemosensitizing activity in human leukemia cellsGPX3 promoter is methylated in chronic myeloid leukemia.Knock-down of Kaiso induces proliferation and blocks granulocytic differentiation in blast crisis of chronic myeloid leukemiaUpregulated TCRζ enhances interleukin-2 production in T-cells from patients with CML.The PERK-eIF2α phosphorylation arm is a pro-survival pathway of BCR-ABL signaling and confers resistance to imatinib treatment in chronic myeloid leukemia cells.Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon-γ.Re-evaluating the role of BCR/ABL in chronic myelogenous leukemiaRetention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy.Expression of BCR/ABL p210 from a knockin allele enhances bone marrow engraftment without inducing neoplasiaUpsides and downsides to polarity and asymmetric cell division in leukemia.Persistence of leukemia-initiating cells in a conditional knockin model of an imatinib-responsive myeloproliferative disorder.Genome-wide profiling of genetic alterations in acute lymphoblastic leukemia: recent insights and future directions.Upregulating miR-146a by physcion reverses multidrug resistance in human chronic myelogenous leukemia K562/ADM cells.Overcoming resistance in chronic myelogenous leukemia.Chronic myeloid leukemia stem cells and developing therapies.The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard dose.
P2860
Q21245701-70BF1140-F84F-40EA-820D-470BFA0653C4Q24293191-81600523-409F-45E1-AA16-8CA5F80C0818Q24626837-FC6BCE43-C9D3-409E-8724-B3D743118C90Q26828528-E792E902-C564-4112-9E5A-870BEB4AA8FDQ26996826-510729FA-71CE-444C-A954-A37344F00C80Q27333786-1E610981-B392-4A04-BC86-11277C797DA0Q27692583-2AF9B4F6-88B7-4347-9628-CEA019DF7304Q29617990-78DDA124-C095-43AB-A270-5207CF0283DEQ30008755-8FDABEB3-06B2-4606-A770-CEFAC390B6E2Q33517413-8A318B63-B32E-41BE-94B6-C702E3B08C9EQ33608760-C9224586-A679-4B71-8E26-F89D7226DD17Q33916841-3A958DC0-46F1-417F-A466-7C1133E2FE2FQ34032508-58FDA466-0EB4-44BB-9508-9473F6A1F636Q34184723-2939096E-CF0D-404E-9708-BA6ABA57DFF0Q34425602-7962D4E7-B6A7-4E7E-8693-702729148FF8Q34443802-017E756C-865C-472D-80AB-B80FF99132EAQ34523506-129A8AE3-3BC0-488F-8EA0-CE3B0EB3CB40Q34555770-6FC18052-BE25-4E08-87CF-9F23B2770FF7Q34645214-9D3ADF0D-4C63-45E2-9475-33C0C4AC0C34Q35016953-61B9C798-A0A5-4288-8BC7-77F297CC4699Q35096609-C931CFC6-01F7-4D0D-9DB9-C882E9F72D49Q35141800-4CFAC103-9518-41E0-99D0-246019941576Q35627994-E28BEC50-C53D-4785-9183-1A807B149617Q35832499-CC0A034C-9391-411C-B147-9268946E1813Q35919012-9C41D031-DA26-4520-BCE0-8C71965B1CD4Q36288848-64827BAE-C5EE-4ED8-AB3B-0D01809AA3AAQ36350996-E52A53AA-2711-4C29-A04F-32239379FD42Q36426519-D6478DB1-E10F-4848-A761-75D850B66D87Q36544358-F0D8B7D0-C12F-42C0-8CAB-A93CB7F52AC9Q36694195-944BB82A-76CE-4BC6-9F1B-DA1A22F40AEBQ36997520-854A23DD-1321-45F7-8BA7-6970026645A6Q37060530-ED751E3B-A95B-491F-819A-ED6717DE975BQ37320065-0FE5806F-C218-4D78-8BEC-0E68EDF2B3FFQ37333623-518627F7-E7C1-4275-BDEA-881DF56AA99EQ37390598-4D953DF3-2C24-4154-B198-E2F1B9F3F1BAQ37401075-CACEE7DF-6CAE-49E2-A05D-D0347EE066E9Q37447892-712F044D-FD1D-4A5A-8C8A-EA301AC3503DQ37626054-024E6E76-F94E-47BE-A443-C9E0932D1B9EQ37836936-6ECE70CA-80EE-40E8-A0D4-375A1A4181E1Q37896606-C9C69B14-C197-44CC-8AA9-198EAFC93CE8
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Getting to the stem of chronic myeloid leukaemia.
@en
Getting to the stem of chronic myeloid leukaemia.
@nl
type
label
Getting to the stem of chronic myeloid leukaemia.
@en
Getting to the stem of chronic myeloid leukaemia.
@nl
prefLabel
Getting to the stem of chronic myeloid leukaemia.
@en
Getting to the stem of chronic myeloid leukaemia.
@nl
P2860
P356
P1476
Getting to the stem of chronic myeloid leukaemia.
@en
P2093
Moshe Talpaz
P2860
P2888
P304
P356
10.1038/NRC2368
P407
P577
2008-05-01T00:00:00Z
P6179
1020611190